Lung Infection
33
6
7
12
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
15.2%
5 terminated out of 33 trials
70.6%
-15.9% vs benchmark
9%
3 trials in Phase 3/4
33%
4 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (33)
FMT for Lung and Associated-organ Rescue Efficacy in MDRO-infected Ventilated Patients
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
UNC Pleural Fluid Registry
Next-generation Sequencing Technology in the Clinical Application of Respiratory Specimens
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
Evaluation of Virtual Reality to Reduce Anxiety, Pain and Duration of Non-emergency Vigile Bronchial Fibroscopy (AVATAR)
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
A Study of the Clinical Benefit of Tobramycin Inhalation Solution
Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
Effects of Prone Position After Major Abdominal Surgery
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
Biomarker for Cystic Fibrosis
Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)
Population Pharmacokinetics of Lassila Tazobactam in Patients After Aortic Dissection
COVID-19 and Lung Ultrasound Utility
Aerosolisation During Respiratory Procedures